• Sarah Prichard, MD, has been named vice president of global medical affairs forBaxter International’s (Deerfield, Illinois) Renal business. Prichard will be joining Baxter in June, and in her new role will be overseeing all scientific, clinical and medical affairs globally for the Renal business unit. Prichard currently serves as professor of medicine at McGill University and senior physician and director of peritoneal dialysis for the Royal Victoria Hospital (both Montreal).

• James Bracke, PhD, has joined Epien (White Bear Lake, Minnesota) as chief operating officer. Bracke was previously a founding scientist, director, president and CEO of Lifecore Biomedical. Epien Medical is focused on developing novel agents for the repair of damaged skin.

• Gordon Snyder has been named vice president of sales at FlowMedica (Fremont, California), a company focused on the prevention and treatment of acute kidney failure in the setting of cardiovascular disease and surgery. Previously, Snyder was the director of sales, North America, at Novoste.

• Michael Wood, a former academic researcher and GE business leader, has been promoted to the newly created position of general manager of research collaborations for the Global Magnetic Resonance business of GE Healthcare (Waukesha, Wisconsin).

• Pressure BioSciences (West Bridgewater, New Jersey) has appointed Steven Hebert as CFO, vice president of finance and assistant treasurer. Hebert has recently served as a part-time financial consultant to the company, and previously was vice president of finance and corporate controller for Brooks Automation. The company also hired Jose Lanuza as director of sales. For nearly 30 years, Lanuza has served as a senior sales executive for a number of life sciences companies, including Cliniqa, Medical Analysis Systems, Serono, Hybritech and Abbott Laboratories. Pressure BioSciences, formerly Boston Biomedical, is focused on the development of Pressure Cycling Technology, which uses cycles of hydrostatic pressure to control bio-molecular interactions.

• Bernard Pitz has been named vice president-finance, CFO and treasurer of Sybron Dental Specialties (Orange, California), effective May 11. Pitz joined the company on March 1 with the intention of succeeding Gregory Waller, current vice president-finance, CFO and treasurer, upon his retirement on May 10. Sybron Dental Specialties and its subsidiaries manufacture consumable general dental and specialty products for the orthodontic, endodontic, implant and infection prevention markets worldwide.

• Dr. James Posillico has been named president and CEO of Vitro Diagnostics (Aurora, Colorado). Posillico, who also is a director of the company, has extensive prior experience as an executive of pharmaceutical and medical device firms, including Serono and Cooper Surgical. Posillico replaces Dr. James Musick as president and CEO. Musick has been named chairman of the board, chief operating officer and secretary, and retains his position as CFO. Vitro Diagnostics develops the Vitrocell brand of human cell lines consisting of pituitary and pancreatic-derived cell lines and related products, including optimized growth medium and other products needed for culture of the cell lines.